Early Angiogenic Proteins Associated with High Risk for Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Infants.
Early Angiogenic Proteins Associated with High Risk for Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Infants. Am J Physiol Lung Cell Mol Physiol. 2020 Jan 22;: Authors: Arjaans S, Wagner BD, Mourani PM, Mandell EW, Poindexter BB, Berger RMF, Abman SH Abstract INTRODUCTION: Early pulmonary vascular disease in preterm infants is associated with the subsequent development of bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH), however, mechanisms that contribute to or identify infants with increased susceptibility for BPD and/or PH are incompletely understood. Therefore, we tested if changes in circulating angiogenic peptides during the first week of life are associated with the later development of BPD and/or PH. We further sought to determine alternate peptides and related signalling pathways with the risk for BPD or PH. METHODS: We prospectively enrolled infants with gestational age
Abstract Bronchopulmonary dysplasia (BPD), which remains a major clinical problem for preterm infants, is caused mainly by hyperoxia, mechanical ventilation and inflammation. Many approaches have been developed with the aim of decreasing the incidence of or alleviating BPD, but effective methods are still lacking. Gasotransmitters, a type of small gas molecule that can be generated endogenously, exert a protective effect against BPD-associated lung injury; nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H2S) are three such gasotransmitters. The protective effects of NO have been extensively studied i...
Abstract RATIONALE: Bronchopulmonary dysplasia (BPD) is a heterogenous condition with poorly characterized disease subgroups. OBJECTIVES: To define the frequency of three disease components: moderate-severe parenchymal disease, pulmonary hypertension (PH), or large airway disease, in a referral cohort of preterm infants with severe BPD. The association between each component and a primary composite outcome of death prior to hospital discharge, tracheostomy, or home pulmonary vasodilator therapy was assessed. METHODS: Retrospective, single center cohort study of infants born
This article reviews the current drug therapies and their use in the management of PAH in children.
This article reviews the current drug therapies and their use in the management of PAH in children. PMID: 31960361 [PubMed - as supplied by publisher]
The clinical utility of echocardiography for the diagnosis of pulmonary vascular disease (PVD) in former preterm infants with bronchopulmonary dysplasia (BPD) is not established. Elevated pulmonary vascular resistance (PVR) rather than pulmonary artery pressure (PAP) is the hallmark of PVD. We evaluated the utility of echocardiography in infants with BPD in diagnosing pulmonary hypertension and PVD (PVR>3 Wood units × m2) assessed by cardiac catheterization.
Publication date: Available online 20 December 2019Source: Nitric OxideAuthor(s): Julie Dillard, Marta Perez, Bernadette ChenAbstractThere are several pulmonary hypertensive diseases that affect the neonatal population, including persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH). While the indication for inhaled nitric oxide (iNO) use is for late-preterm and term neonates with PPHN, there is a suboptimal response to this pulmonary vasodilator in ∼40% of patients. Additionally, there are no FDA-approved treatments for BPD-associated PH or ...
Conclusions: Patients with chILD are evaluated in a wide spectrum according to age of diagnosis, symptoms, underlying diseases or radiological findings. It is important for clinicians to keep in mind chILD in terms of early diagnosis and possible treatments in children with dyspnea, pulmonary infiltration, hypoxia or restrictive disorder in pulmonary function tests.
The original description of bronchopulmonary dysplasia (BPD) included the finding that pulmonary vascular disease and right ventricular hypertrophy are associated with the high mortality of the disease.1 Today, chronic pulmonary hypertension persists as a major cause of morbidity and mortality of extremely premature infants.2,3 Although pulmonary hypertension can present in premature infants at different stages with varying hemodynamic signatures during the neonatal course, chronic pulmonary hypertension is characterized by late, sustained, and often progressive elevation of pulmonary artery pressure (PAP) that is diagnose...
Pediatric Allergy, Immunology, and Pulmonology, Ahead of Print.
Journal of Perinatology, Published online: 13 November 2019; doi:10.1038/s41372-019-0549-9Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia